Skip to content

To know the effect of Dwipanchamooladi Basti and Varunadi Kwatha in Chronic Kidney Disease

A clinical evaluation of Dwipanchamooladi Basti and oral administration of Varunadi kwatha as an adjuvent therapy in vrikka roga with special reference to Chronic kidney disease - NIL

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/02/103777
Enrollment
30
Registered
2026-02-12
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N189- Chronic kidney disease, unspecified

Interventions

None listed

Sponsors

Government P.G Ayurveda College and Hospital, Chaukaghat Varanasi-221002, U.P, India
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Participants who give consent for participate for the study,among the age group 20 -60 years irrespective of gender, religion and caste and present with the history and symptoms of Vrikka Roga (Chronic kidney disease and condition lies in between the mild to moderate stage(3B) of chronic kidney disease classification with clinical evidence of chronic kidney disease with eGFR ranging from 30 -90ml/min/1.73 m2.

Exclusion criteria

Exclusion criteria: Patients unfit for basti procedure having uncontrolled hypertension (systolic more than 200 mm Hg .diastolic more than 100 mmHg) with haemoglobin level less than 8g/dl. Participants with other co-existing complication like hyperkalemia, hypoglycemia , hyponatremia and diagnosed congenital, inherited disorders and infective conditions with cardio-vascular diseases, and on haemodialysis. Patients diagnosed with type 2 diabetes mellitus and with uncontrol sugar level and HbA1c more than 7.If in ultrasonography if cortico-medullary junction differentiation is lost.

Design outcomes

Primary

MeasureTime frame
Primary outcome measure is objective based on the biochemical parameter, serum creatinine and eGFR.Timepoint: 8th day,16th day and 24th day

Secondary

MeasureTime frame
Secondary outcome is measured in the improvement of haemoglobinn level,serum electrolytes, urine output along with correction in blood pressure level.Timepoint: 8th day,16th day and 24th day

Countries

India

Contacts

Public ContactDr Manish Mishra

Government P.G Ayurveda College and Hospital, Chaukaghat Varanasi, U.P

manish.arnav@gmail.com9415896482

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 11, 2026